Loading...

ABBV

AbbVie, Inc. · NYSE

Performance

+4.69%

1W

+4.32%

1M

-5.34%

3M

+14.49%

6M

+10.29%

YTD

+26.72%

1Y

Profile

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; California Institute for Biomedical Research (Calibr), and BigHat Biosciences, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Investment Analysis Report: ABBV

Overview:

AbbVie Inc. (ABBV) operates in the Health Technology sector, specifically in the Pharmaceuticals: Major industry. The company has a market capitalization of $314.59 billion. In this report, we will conduct a detailed analysis of ABBV's financial health, valuation, earnings and revenue growth, profitabil...

See more ...

Technical Analysis of ABBV 2024-05-31

Overview:

In analyzing the technical indicators for ABBV over the last 5 days, we will delve into the trends, momentum, volatility, and volume aspects to provide a comprehensive outlook on the possible stock price movement. By examining key indicators such as moving averages, MACD, RSI, Bollinger Bands, and OBV, we aim to offer valuable insights...

See more ...

Recent News & Updates